Please try another search
For the six months ended 30 June 2018, Sinclair Pharma PLC revenues increased 6% to £21.3M. Net loss before extraordinary items increased 61% to £11.5M. Revenues reflect European direct segment increase of 31% to £8.2M, Asia Pacific segment increase of 49% to £5.5M. Higher net loss reflects Inventory provision increase from £0K to £1.9M (expense), Administrative expenses increase of 7% to £8.9M (expense).
Period Ending: | Jun 30, 2018 | Dec 31, 2017 | Jun 30, 2017 | Dec 31, 2016 |
---|---|---|---|---|
Total Revenue | 21.26 | 25.25 | 20.05 | 20.57 |
Gross Profit | 14.81 | 18.36 | 14.53 | 14.14 |
Operating Income | -8.47 | 3.37 | -5.53 | -7.12 |
Net Income | -11.49 | 6.95 | -6.99 | -14.26 |
Period Ending: | Jun 30, 2018 | Dec 31, 2017 | Jun 30, 2017 | Dec 31, 2016 |
---|---|---|---|---|
Total Assets | 168.74 | 168.88 | 165.96 | 184.6 |
Total Liabilities | 79.94 | 69.69 | 73.08 | 84.28 |
Total Equity | 88.8 | 99.18 | 92.88 | 100.32 |
Period Ending: | Jun 30, 2018 | Dec 31, 2017 | Jun 30, 2017 | Dec 31, 2016 |
---|---|---|---|---|
Period Length: | 6 Months | 12 Months | 6 Months | 18 Months |
Cash From Operating Activities | -8.4 | -11.02 | -10.35 | -19.28 |
Cash From Investing Activities | -3.79 | -8.83 | -6.19 | 79.23 |
Cash From Financing Activities | 13.71 | 5 | 3 | -56.67 |
Net Change in Cash | 1.54 | -14.93 | -13.61 | 4.11 |
Unlock access to over 1000 metrics with InvestingPro
View advanced insights on financial statements, including growth rates and metrics that provide an in-depth view of the company's historical and forecasted financial performance.
Are you sure you want to block %USER_NAME%?
By doing so, you and %USER_NAME% will not be able to see any of each other's Investing.com's posts.
%USER_NAME% was successfully added to your Block List
Since you’ve just unblocked this person, you must wait 48 hours before renewing the block.
I feel that this comment is:
Thank You!
Your report has been sent to our moderators for review